Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity

Bald, 2014, Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation, Cancer Discov., 4, 674, 10.1158/2159-8290.CD-13-0458 Balkwill, 2005, Smoldering and polarized inflammation in the initiation and promotion of malignant disease, Cancer Cell, 7, 211, 10.1016/j.ccr.2005.02.013 Becker, 2009, COX-2 expression in malignant melanoma: a novel prognostic marker?, Melanoma Res., 19, 8, 10.1097/CMR.0b013e32831d7f52 Broz, 2014, Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity, Cancer Cell, 26, 638, 10.1016/j.ccell.2014.09.007 Castle, 2014, Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma, BMC Genomics, 15, 190, 10.1186/1471-2164-15-190 Chen, 2015, Prostaglandin E2 and programmed cell death 1 signaling coordinately impair CTL function and survival during chronic viral infection, Nat. Med., 21, 327, 10.1038/nm.3831 Coulombe, 2014, Targeted prostaglandin E2 inhibition enhances antiviral immunity through induction of type I interferon and apoptosis in macrophages, Immunity, 40, 554, 10.1016/j.immuni.2014.02.013 Coussens, 2013, Neutralizing tumor-promoting chronic inflammation: a magic bullet?, Science, 339, 286, 10.1126/science.1232227 Dannenberg, 2003, Targeting cyclooxygenase-2 in human neoplasia: rationale and promise, Cancer Cell, 4, 431, 10.1016/S1535-6108(03)00310-6 Denkert, 2001, Expression of cyclooxygenase 2 in human malignant melanoma, Cancer Res., 61, 303 Dhomen, 2009, Oncogenic Braf induces melanocyte senescence and melanoma in mice, Cancer Cell, 15, 294, 10.1016/j.ccr.2009.02.022 Diamond, 2011, Type I interferon is selectively required by dendritic cells for immune rejection of tumors, J. Exp. Med., 208, 1989, 10.1084/jem.20101158 Dunn, 2005, A critical function for type I interferons in cancer immunoediting, Nat. Immunol., 6, 722, 10.1038/ni1213 DuPage, 2012, Expression of tumour-specific antigens underlies cancer immunoediting, Nature, 482, 405, 10.1038/nature10803 Frederick, 2013, BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma, Clin. Cancer Res., 19, 1225, 10.1158/1078-0432.CCR-12-1630 Fridman, 2012, The immune contexture in human tumours: impact on clinical outcome, Nat. Rev. Cancer, 12, 298, 10.1038/nrc3245 Frock, 2015, Genome-wide detection of DNA double-stranded breaks induced by engineered nucleases, Nat. Biotechnol., 33, 179, 10.1038/nbt.3101 Fuertes, 2011, Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8alpha+ dendritic cells, J. Exp. Med., 208, 2005, 10.1084/jem.20101159 Gajewski, 2010, Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy, Cancer J., 16, 399, 10.1097/PPO.0b013e3181eacbd8 Gajewski, 2013, Innate and adaptive immune cells in the tumor microenvironment, Nat. Immunol., 14, 1014, 10.1038/ni.2703 Gamba, 2013, Aspirin is associated with lower melanoma risk among postmenopausal Caucasian women: the Women’s Health Initiative, Cancer, 119, 1562, 10.1002/cncr.27817 Gierach, 2008, Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Health-AARP Diet and Health Study, Breast Cancer Res., 10, R38, 10.1186/bcr2089 Goulet, 2003, Analysis of cyclooxygenase 2 (COX-2) expression during malignant melanoma progression, Cancer Biol. Ther., 2, 713, 10.4161/cbt.2.6.627 Grivennikov, 2010, Immunity, inflammation, and cancer, Cell, 140, 883, 10.1016/j.cell.2010.01.025 Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 Helft, 2015, GM-CSF mouse bone marrow cultures comprise a heterogeneous population of CD11c(+)MHCII(+) macrophages and dendritic cells, Immunity, 42, 1197, 10.1016/j.immuni.2015.05.018 Hildner, 2008, Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity, Science, 322, 1097, 10.1126/science.1164206 Joyce, 2015, T cell exclusion, immune privilege, and the tumor microenvironment, Science, 348, 74, 10.1126/science.aaa6204 Kalinski, 2012, Regulation of immune responses by prostaglandin E2, J. Immunol., 188, 21, 10.4049/jimmunol.1101029 Knight, 2013, Host immunity contributes to the anti-melanoma activity of BRAF inhibitors, J. Clin. Invest., 123, 1371, 10.1172/JCI66236 Kuźbicki, 2006, Expression of cyclooxygenase-2 in benign naevi and during human cutaneous melanoma progression, Melanoma Res., 16, 29, 10.1097/01.cmr.0000194430.77643.a0 Mantovani, 2008, Cancer-related inflammation, Nature, 454, 436, 10.1038/nature07205 Matsushita, 2012, Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting, Nature, 482, 400, 10.1038/nature10755 Mayer-Barber, 2014, Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk, Nature, 511, 99, 10.1038/nature13489 Page, 2014, Immune modulation in cancer with antibodies, Annu. Rev. Med., 65, 185, 10.1146/annurev-med-092012-112807 Pedersen, 2013, Primary melanoma of the CNS in children is driven by congenital expression of oncogenic NRAS in melanocytes, Cancer Discov., 3, 458, 10.1158/2159-8290.CD-12-0464 Phan, 2013, Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment, Proc. Natl. Acad. Sci. USA, 110, 6079, 10.1073/pnas.1303302110 Rakoff-Nahoum, 2009, Toll-like receptors and cancer, Nat. Rev. Cancer, 9, 57, 10.1038/nrc2541 Ricciotti, 2011, Prostaglandins and inflammation, Arterioscler. Thromb. Vasc. Biol., 31, 986, 10.1161/ATVBAHA.110.207449 Rooney, 2015, Molecular and genetic properties of tumors associated with local immune cytolytic activity, Cell, 160, 48, 10.1016/j.cell.2014.12.033 Rothwell, 2010, Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials, Lancet, 376, 1741, 10.1016/S0140-6736(10)61543-7 Ruffell, 2014, Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells, Cancer Cell, 26, 623, 10.1016/j.ccell.2014.09.006 Schreiber, 2011, Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion, Science, 331, 1565, 10.1126/science.1203486 Sharma, 2015, The future of immune checkpoint therapy, Science, 348, 56, 10.1126/science.aaa8172 Talantov, 2005, Novel genes associated with malignant melanoma but not benign melanocytic lesions, Clin. Cancer Res., 11, 7234, 10.1158/1078-0432.CCR-05-0683 Tian, 2010, Meta-analysis on the relationship between nonsteroidal anti-inflammatory drug use and gastric cancer, Eur. J. Cancer Prev., 19, 288, 10.1097/CEJ.0b013e328339648c Vesely, 2011, Natural innate and adaptive immunity to cancer, Annu. Rev. Immunol., 29, 235, 10.1146/annurev-immunol-031210-101324 Wang, 2010, Eicosanoids and cancer, Nat. Rev. Cancer, 10, 181, 10.1038/nrc2809 Wenzel, 2005, Type I interferon-associated recruitment of cytotoxic lymphocytes: a common mechanism in regressive melanocytic lesions, Am. J. Clin. Pathol., 124, 37, 10.1309/4EJ9KL7CGDENVVLE Willimsky, 2005, Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance, Nature, 437, 141, 10.1038/nature03954 Xu, 2014, COX-2 inhibition potentiates antiangiogenic cancer therapy and prevents metastasis in preclinical models, Sci. Transl. Med., 6, 242ra84, 10.1126/scitranslmed.3008455